文献速递白血病

ASXL1突变预测慢性髓性白血病患者对尼洛替尼治疗的分子学反应不佳

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
PubMed 文献 · Leukemia · 2022-07-28

在TIGER研究(CML-V)的222例慢性期慢性髓性白血病患者中,采用覆盖54个髓系白血病相关基因的靶向二代测序分析体细胞突变的患病率、动态变化及预后意义。53/222例(24%)患者在诊断时携带60个突变,ASXL1最常见(n=20)。诊断时携带ASXL1突变的患者接受尼洛替尼治疗后,12、18和24个月的主要分子学反应(MMR)获得率低于所有其他患者。

要点

  • 53/222例(24%)慢性期CML患者在诊断时携带体细胞突变,ASXL1为最常见突变基因(n=20)。
  • 诊断时携带ASXL1突变的患者接受尼洛替尼治疗后12、18和24个月MMR获得率低于所有其他患者。
  • ASXL1突变患者更年轻且更多见于高危类别,提示ASXL1相关克隆演化在CML发病中可能起核心作用。

核心结论

  • 诊断时携带ASXL1突变的慢性期CML患者对尼洛替尼治疗的分子学反应较差,12、18和24个月MMR获得率低于所有其他患者。

研究设计与样本

  • 研究纳入TIGER研究(CML-V)中222例临床特征明确的CML患者,采用覆盖54个髓系白血病相关基因的靶向二代测序分析突变。
  • 对100例患者在治疗12、24和36个月后进行连续样本的纵向深度测序以分析突变动态。

主要发现

  • 53/222例(24%)CML患者在诊断时携带60个突变,ASXL1为最常受累基因(n=20)。
  • 纵向深度测序显示克隆演化的典型模式包括突变克隆的清除、持续和出现。
  • 诊断时携带ASXL1突变的患者12、18和24个月MMR获得率低于所有其他患者。
  • ASXL1突变患者更年轻且更多见于高危类别。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene mutations independent of BCR::ABL1 have been identified in newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in epigenetic modifier genes were most common. These findings prompted the systematic analysis of prevalence, dynamics, and prognostic significance of such mutations, in a clinically well-characterized patient population of 222 CML patients from the TIGER study (CML-V) by targeted next-generation sequencing covering 54 myeloid leukemia-associated genes. In total, 53/222 CML patients (24%) carried 60 mutations at diagnosis with ASXL1 being most commonly affected (n = 20). To study mutation dynamics, longitudinal deep sequencing analysis of serial samples was performed in 100 patients after 12, 24, and 36 months of therapy. Typical patterns of clonal evolution included eradication, persistence, and emergence of mutated clones. Patients carrying an ASXL1 mutation at diagnosis showed a less favorable molecular response to nilotinib treatment, as a major molecular response (MMR) was achieved less frequently at month 12, 18, and 24 compared to all other patients. Patients with ASXL1 mutations were also younger and more frequently found in the high risk category, suggesting a central role of clonal evolution associated with ASXL1 mutations in CML pathogenesis.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Schönfeld L, Rinke J, Hinze A, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022. PMID: 35902731. doi:10.1038/s41375-022-01648-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。